.png)
Jiangsu New Xinlong Pharmaceutical Technology Co., Ltd. and Hubei Huaxing New Material Technology Co., Ltd. are the subsidiaries of Suzhou Xinlong Chemical Co., Ltd. Founded in 1998 and located in Suzhou (a beautiful town in Yangtze river delta), Xinlong now is a comprehensive and modern manufacturing enterprise mainly engaged in research and development, production, sales and trade of pharmaceutical intermediates and new materials, as well as the contract customization and processing; we now have two production bases, and our products are widely used in pharmaceuticals, veterinary drugs, pesticides, dyes and new materials, etc. With the right to have import and export business independently, we are an AAA- credit-ranking enterprise.
Jiangsu Xinxinlong Pharmaceutical Technology Co., Ltd. was founded in 2006; located in Lingang Industrial Zone (a province-level chemical park) of the Guanyun County in Jiangsu Province, Jiangsu Xinxinlong Pharmaceutical Technology Co., Ltd. covers an area of ??nearly 100,050 square meters.
Hubei Huaxing New Material Technology Co., Ltd. was established in 2019; now, it is located in Jintongling Industrial Park (a province-level chemical park) of the Zhuxi County in Hubei Province, Hubei Huaxing New Material Technology Co., Ltd. covers an area of ??nearly 240,120 square meters.
Following customers' demands, our company has successfully established a stable and reliable quality assurance system and achieved a good corporation image; now, our company has fully implemented digital automated production. There are more than 300 employees, nearly 70% of our employees have a college degree or above; graduated from well-known institutions and universities across the country; all of them are playing an important role in the scientific research, production and management of our company. At present, our company has started to build a two-stage R&D center and a multi-functional incubation plant, and has formed an industrial alliance with a number of universities to actively improve and enrich our product line; through unswervingly introducing a doctoral team, we have laid a solid foundation for the establishment of our doctoral workstation in the future .
Our future development direction will advocate low-carbon economy, integrate our own resource to optimize the product structure and accelerate industrial upgrading, and then we strive to be a domestic leading innovative enterprise with strong international competitive awareness and capabilities in the near future; we will never forget our social responsibility, so we are going to make unremitting efforts for the happy life of employees, the healthy development of the national pharmaceutical industry, and the domestic substitution of new materials; at the same time, we also firmly believe that in the historical opportunity of Made in China 2025, we will continue to achieve new leaps and new breakthroughs of our company.
